Published in Science on June 01, 2001
Structural basis for engagement by complement factor H of C3b on a self surface. Nat Struct Mol Biol (2011) 2.32
Structure of complement factor H carboxyl-terminus reveals molecular basis of atypical haemolytic uremic syndrome. EMBO J (2006) 1.72
Complement System Part I - Molecular Mechanisms of Activation and Regulation. Front Immunol (2015) 1.52
Complement receptor 2-mediated targeting of complement inhibitors to sites of complement activation. J Clin Invest (2003) 1.46
Epitope-mapping studies define two major neutralization sites on the vaccinia virus extracellular enveloped virus glycoprotein B5R. J Virol (2005) 1.44
Cancer vaccines and carbohydrate epitopes. Vaccine (2011) 1.40
The structure of human CD23 and its interactions with IgE and CD21. J Exp Med (2005) 1.28
The crystal structure of human CD21: Implications for Epstein-Barr virus and C3d binding. Proc Natl Acad Sci U S A (2002) 1.11
Electrostatic contributions drive the interaction between Staphylococcus aureus protein Efb-C and its complement target C3d. Protein Sci (2008) 1.09
The structure of OMCI, a novel lipocalin inhibitor of the complement system. J Mol Biol (2007) 1.09
Cutting edge: members of the Staphylococcus aureus extracellular fibrinogen-binding protein family inhibit the interaction of C3d with complement receptor 2. J Immunol (2008) 1.07
Abeta DNA vaccination for Alzheimer's disease: focus on disease prevention. CNS Neurol Disord Drug Targets (2010) 1.02
Concern Structure of vaccinia complement protein in complex with heparin and potential implications for complement regulation. Proc Natl Acad Sci U S A (2004) 1.00
A structural model reveals energy transduction in dynein. Proc Natl Acad Sci U S A (2006) 0.98
Constrained solution scattering modelling of human antibodies and complement proteins reveals novel biological insights. J R Soc Interface (2009) 0.97
The central portion of factor H (modules 10-15) is compact and contains a structurally deviant CCP module. J Mol Biol (2009) 0.96
Immunophysical properties and prediction of activities for vaccinia virus complement control protein and smallpox inhibitor of complement enzymes using molecular dynamics and electrostatics. Biophys J (2006) 0.94
App1: an antiphagocytic protein that binds to complement receptors 3 and 2. J Immunol (2009) 0.93
Complement receptors and the shaping of the natural antibody repertoire. Springer Semin Immunopathol (2004) 0.90
Molecular basis of the interaction between complement receptor type 2 (CR2/CD21) and Epstein-Barr virus glycoprotein gp350. J Virol (2008) 0.89
Solution structure of CCP modules 10-12 illuminates functional architecture of the complement regulator, factor H. J Mol Biol (2012) 0.86
The structure of C2b, a fragment of complement component C2 produced during C3 convertase formation. Acta Crystallogr D Biol Crystallogr (2009) 0.85
Amino acid patterns within short consensus repeats define conserved duplicons shared by genes of the RCA complex. J Mol Evol (2004) 0.84
Two-step fluorescence screening of CD21-binding peptides with one-bead one-compound library and investigation of binding properties of N-(2-hydroxypropyl)methacrylamide copolymer-peptide conjugates. Biomacromolecules (2006) 0.84
Use of time-resolved FRET to validate crystal structure of complement regulatory complex between C3b and factor H (N terminus). Protein Sci (2011) 0.84
Mapping of the C3d ligand binding site on complement receptor 2 (CR2/CD21) using nuclear magnetic resonance and chemical shift analysis. J Biol Chem (2009) 0.83
Molecular analysis of the interaction between staphylococcal virulence factor Sbi-IV and complement C3d. Biophys J (2014) 0.83
A structural basis for Staphylococcal complement subversion: X-ray structure of the complement-binding domain of Staphylococcus aureus protein Sbi in complex with ligand C3d. Mol Immunol (2010) 0.82
Zinc-induced self-association of complement C3b and Factor H: implications for inflammation and age-related macular degeneration. J Biol Chem (2013) 0.82
Human complement receptor 2 (CR2/CD21) as a receptor for DNA: implications for its roles in the immune response and the pathogenesis of systemic lupus erythematosus (SLE). Mol Immunol (2012) 0.81
Focused transcription from the human CR2/CD21 core promoter is regulated by synergistic activity of TATA and Initiator elements in mature B cells. Cell Mol Immunol (2015) 0.79
Comparison of tertiary structures of proteins in protein-protein complexes with unbound forms suggests prevalence of allostery in signalling proteins. BMC Struct Biol (2012) 0.79
Energetic evaluation of binding modes in the C3d and Factor H (CCP 19-20) complex. Protein Sci (2015) 0.79
C3d adjuvant activity is reduced by altering residues involved in the electronegative binding of C3d to CR2. Immunol Lett (2010) 0.77
Separation of decay-accelerating and cofactor functional activities of Kaposi's sarcoma-associated herpesvirus complement control protein using monoclonal antibodies. Immunology (2007) 0.76
Antigen archiving by lymph node stroma: A novel function for the lymphatic endothelium. Eur J Immunol (2015) 0.76
Electrostatic Steering Accelerates C3d:CR2 Association. J Phys Chem B (2016) 0.75
The structure and function of thioester-containing proteins in arthropods. Biophys Rev (2014) 0.75
Molecular structure and expression of anthropic, ovine, and murine forms of complement receptor type 2. Clin Vaccine Immunol (2008) 0.75
Antiphospholipid syndrome patients display reduced titers of soluble CD21 in their sera irrespective of circulating anti-beta2-glycoprotein-I autoantibodies. Rheumatol Int (2008) 0.75
Proton NMR chemical shifts and coupling constants for brain metabolites. NMR Biomed (2000) 8.18
ErbB2, but not ErbB1, reinitiates proliferation and induces luminal repopulation in epithelial acini. Nat Cell Biol (2001) 6.21
Chemoprevention of gastric dysplasia: randomized trial of antioxidant supplements and anti-helicobacter pylori therapy. J Natl Cancer Inst (2000) 4.51
Molecular basis of phenotypic variability in sporadic Creutzfeldt-Jakob disease. Ann Neurol (1996) 4.10
Randomized, comparative study of interferon beta-1a treatment regimens in MS: The EVIDENCE Trial. Neurology (2002) 3.73
Detection of coronary stenoses on source and projection images using three-dimensional MR angiography with retrospective respiratory gating: preliminary experience. AJR Am J Roentgenol (1998) 3.58
Cardiotoxicity after accidental herb-induced aconite poisoning. Lancet (1992) 3.43
A critical role for murine complement regulator crry in fetomaternal tolerance. Science (2000) 3.27
In vivo visualization of myelin water in brain by magnetic resonance. Magn Reson Med (1994) 3.25
Gene expression profiling of cells, tissues, and developmental stages of the nematode C. elegans. Cold Spring Harb Symp Quant Biol (2003) 3.22
KLF6, a candidate tumor suppressor gene mutated in prostate cancer. Science (2001) 3.22
Automated spectral analysis III: application to in vivo proton MR spectroscopy and spectroscopic imaging. Magn Reson Med (1998) 3.16
A new scoring system for the chances of identifying a BRCA1/2 mutation outperforms existing models including BRCAPRO. J Med Genet (2004) 3.10
Development of a symptom distress scale. Cancer Nurs (1978) 2.78
A Phase II study of the safety and efficacy of teriflunomide in multiple sclerosis with relapses. Neurology (2006) 2.75
Markedly impaired humoral immune response in mice deficient in complement receptors 1 and 2. Proc Natl Acad Sci U S A (1996) 2.71
Genetic deletion of the Pten tumor suppressor gene promotes cell motility by activation of Rac1 and Cdc42 GTPases. Curr Biol (2000) 2.67
Long-term subcutaneous interferon beta-1a therapy in patients with relapsing-remitting MS. Neurology (2006) 2.64
The regulators of complement activation (RCA) gene cluster. Adv Immunol (1989) 2.63
Cloning and characterization of cDNAs encoding the complete sequence of decay-accelerating factor of human complement. Proc Natl Acad Sci U S A (1987) 2.62
Duration of preclinical rheumatoid arthritis-related autoantibody positivity increases in subjects with older age at time of disease diagnosis. Ann Rheum Dis (2007) 2.38
Changing sexual attitudes and behaviour in China: implications for the spread of HIV and other sexually transmitted diseases. AIDS Care (1999) 2.35
Structures of two repeats of spectrin suggest models of flexibility. Cell (1999) 2.30
Intravenous immunoglobulin in relapsing-remitting multiple sclerosis: a dose-finding trial. Neurology (2008) 2.29
Cine MR angiography of the heart with segmented true fast imaging with steady-state precession. Radiology (2001) 2.23
A comparative linkage map of oilseed rape and its use for QTL analysis of seed oil and erucic acid content. Theor Appl Genet (2006) 2.21
Comprehensive processing, display and analysis for in vivo MR spectroscopic imaging. NMR Biomed (2006) 2.19
Follow-up and final results of the Oslo I Study comparing screen-film mammography and full-field digital mammography with soft-copy reading. Acta Radiol (2005) 2.16
Pathogenic implications of mutations in the tau gene in pallido-ponto-nigral degeneration and related neurodegenerative disorders linked to chromosome 17. Proc Natl Acad Sci U S A (1998) 2.13
Magnetic resonance imaging of the upper airway in obstructive sleep apnea before and after chronic nasal continuous positive airway pressure therapy. Am Rev Respir Dis (1991) 2.12
Scoring treatment response in patients with relapsing multiple sclerosis. Mult Scler (2012) 2.07
Airway mucosa: secretory cells, mucus and mucin genes. Eur Respir J (1997) 2.06
Microbial hazards associated with bean sprouting. J Assoc Off Anal Chem (1982) 2.03
3D magnetization-prepared true-FISP: a new technique for imaging coronary arteries. Magn Reson Med (2001) 2.00
Laparoscopic extralevator abdominoperineal excision of the rectum: short-term outcomes of a prospective case series. Tech Coloproctol (2013) 1.99
Infection thread formation as a basis of nodulation specificity in Rhizobium--strawberry clover associations. Can J Microbiol (1969) 1.98
Expression of complement receptors 1 and 2 on follicular dendritic cells is necessary for the generation of a strong antigen-specific IgG response. J Immunol (1998) 1.96
Analysis of clinical outcomes according to original treatment groups 16 years after the pivotal IFNB-1b trial. J Neurol Neurosurg Psychiatry (2010) 1.94
Microsatellite instability in colorectal cancer: improved assessment using fluorescent polymerase chain reaction. Gastroenterology (1995) 1.92
Injecting drug use and HIV infection in southwest China. AIDS (1994) 1.91
Artery and vein separation using susceptibility-dependent phase in contrast-enhanced MRA. J Magn Reson Imaging (2000) 1.91
Essential role of POU-domain factor Brn-3c in auditory and vestibular hair cell development. Proc Natl Acad Sci U S A (1997) 1.88
Corticosteroid reversibility in COPD is related to features of asthma. Am J Respir Crit Care Med (1997) 1.87
Surface signaling in pathogenesis. Proc Natl Acad Sci U S A (1995) 1.81
Balanced biosynthesis of major membrane components through regulated degradation of the committed enzyme of lipid A biosynthesis by the AAA protease FtsH (HflB) in Escherichia coli. Mol Microbiol (1999) 1.80
Neuroprotective potential of ceftriaxone in in vitro models of stroke. Neuroscience (2007) 1.80
Phenotypic variability of Gerstmann-Sträussler-Scheinker disease is associated with prion protein heterogeneity. J Neuropathol Exp Neurol (1998) 1.79
Positron emission tomography in manganese intoxication. Ann Neurol (1989) 1.78
Standardized MR imaging protocol for multiple sclerosis: Consortium of MS Centers consensus guidelines. AJNR Am J Neuroradiol (2006) 1.78
Regulation of gene expression in adult rat hepatocytes cultured on a basement membrane matrix. J Cell Physiol (1988) 1.76
Herpes simplex virus glycoproteins gC-1 and gC-2 bind to the third component of complement and provide protection against complement-mediated neutralization of viral infectivity. J Exp Med (1987) 1.74
Dynamic cerebral autoregulation in sick newborn infants. Pediatr Res (2000) 1.74
Differential effects of alpha- and gamma-tocopherol on low-density lipoprotein oxidation, superoxide activity, platelet aggregation and arterial thrombogenesis. J Am Coll Cardiol (1999) 1.74
Mouse complement regulatory protein Crry/p65 uses the specific mechanisms of both human decay-accelerating factor and membrane cofactor protein. J Exp Med (1995) 1.74
The low density lipoprotein receptor-related protein/alpha2-macroglobulin receptor is a receptor for connective tissue growth factor. J Biol Chem (2001) 1.73
Advanced glycation in D-galactose induced mouse aging model. Mech Ageing Dev (1999) 1.73
P- and E-cadherin are in separate complexes in cells expressing both cadherins. Exp Cell Res (1993) 1.72
Retracted Pre-treatment levels of circulating free IGF-1 identify NSCLC patients who derive clinical benefit from figitumumab. Br J Cancer (2010) 1.69
Cationic lipid-mediated CFTR gene transfer to the lungs and nose of patients with cystic fibrosis: a double-blind placebo-controlled trial. Lancet (1999) 1.69
Allergen-induced IL-9 directly stimulates mucin transcription in respiratory epithelial cells. J Clin Invest (1999) 1.67
Identification of vascular structures as a major source of signal contrast in high resolution 2D and 3D functional activation imaging of the motor cortex at 1.5T: preliminary results. Magn Reson Med (1993) 1.65
The corpus callosum is larger with right-hemisphere cerebral speech dominance. Ann Neurol (1988) 1.64
Prion protein amyloidosis. Brain Pathol (1996) 1.64
Genetic diversity of hantaviruses isolated in china and characterization of novel hantaviruses isolated from Niviventer confucianus and Rattus rattus. Virology (2000) 1.64
An oncogenic role of miR-142-3p in human T-cell acute lymphoblastic leukemia (T-ALL) by targeting glucocorticoid receptor-α and cAMP/PKA pathways. Leukemia (2011) 1.61
Kinetics of eotaxin generation and its relationship to eosinophil accumulation in allergic airways disease: analysis in a guinea pig model in vivo. J Exp Med (1997) 1.61
Neuronal peptide release is limited by secretory granule mobility. Neuron (1997) 1.61
Remodeling of atrial dimensions and emptying function in canine models of atrial fibrillation. Cardiovasc Res (2001) 1.60
Isolation and initial characterization of a newfound hantavirus from California. Virology (1995) 1.59
Skeletal muscle contractile and noncontractile components in young and older women and men. J Appl Physiol (1985) (2000) 1.59
The Ty1-copia group retrotransposons in Vicia species: copy number, sequence heterogeneity and chromosomal localisation. Mol Gen Genet (1996) 1.59
In vitro activities of the potent, broad-spectrum carbapenem MK-0826 (L-749,345) against broad-spectrum beta-lactamase-and extended-spectrum beta-lactamase-producing Klebsiella pneumoniae and Escherichia coli clinical isolates. Antimicrob Agents Chemother (1999) 1.57
Modulation of renal disease in MRL/lpr mice genetically deficient in the alternative complement pathway factor B. J Immunol (2000) 1.55
Parental warmth, control, and indulgence and their relations to adjustment in Chinese children: a longitudinal study. J Fam Psychol (2000) 1.55
An automated communication system in a contact registry for persons with rare diseases: scalable tools for identifying and recruiting clinical research participants. Contemp Clin Trials (2008) 1.52
Mouse Crry/p65. Characterization of monoclonal antibodies and the tissue distribution of a functional homologue of human MCP and DAF. J Immunol (1993) 1.50
Human eHAND, but not dHAND, is down-regulated in cardiomyopathies. J Mol Cell Cardiol (2001) 1.50
Arginine vasopressin stimulates phosphorylation of aquaporin-2 in rat renal tissue. Am J Physiol (1999) 1.50
Structural requirements for C3d,g/Epstein-Barr virus receptor (CR2/CD21) ligand binding, internalization, and viral infection. J Biol Chem (1990) 1.48
Detection of B-mode polarization in the cosmic microwave background with data from the South Pole Telescope. Phys Rev Lett (2013) 1.48
How established wait time benchmarks significantly underestimate total wait times for cardiac surgery. Can J Cardiol (2010) 1.47
Distinct receptor and regulatory properties of recombinant mouse complement receptor 1 (CR1) and Crry, the two genetic homologues of human CR1. J Exp Med (1992) 1.46
Subcellular localization of lethal lysis proteins of bacteriophages lambda and phiX174. J Virol (1985) 1.44
Genomic organization and polymorphisms of the human C3d/Epstein-Barr virus receptor. J Biol Chem (1989) 1.43
Association of rheumatoid arthritis treatment response and disease duration with declines in serum levels of IgM rheumatoid factor and anti-cyclic citrullinated peptide antibody. Arthritis Rheum (2004) 1.43
A detailed analysis of localized J-difference GABA editing: theoretical and experimental study at 4 T. NMR Biomed (2008) 1.42
Ferromagnetism in semihydrogenated graphene sheet. Nano Lett (2009) 1.40
Mouse complement receptors type 1 (CR1;CD35) and type 2 (CR2;CD21): expression on normal B cell subpopulations and decreased levels during the development of autoimmunity in MRL/lpr mice. J Immunol (1997) 1.39
Destabilization and mislocalization of myelin basic protein mRNAs in quaking dysmyelination lacking the QKI RNA-binding proteins. J Neurosci (2000) 1.38
More tips for a successful independent practice. Nurse Pract (1993) 1.38
A collimated, high-speed outflow from the dying star V Hydrae. Nature (2003) 1.37
Cigarette smoking and pancreatic cancer: an analysis from the International Pancreatic Cancer Case-Control Consortium (Panc4). Ann Oncol (2011) 1.36
Cr2, a candidate gene in the murine Sle1c lupus susceptibility locus, encodes a dysfunctional protein. Immunity (2001) 1.36
Pancreatitis and pancreatic cancer risk: a pooled analysis in the International Pancreatic Cancer Case-Control Consortium (PanC4). Ann Oncol (2012) 1.35
Guideline for the diagnosis and management of vitiligo. Br J Dermatol (2008) 1.35
Vaginal ring adherence in sub-Saharan Africa: expulsion, removal, and perfect use. AIDS Behav (2012) 1.35
Interaction of peptides with sequences from the Newcastle disease virus fusion protein heptad repeat regions. J Virol (1999) 1.34
A molecular and immunochemical characterization of mouse CR2. Evidence for a single gene model of mouse complement receptors 1 and 2. J Immunol (1990) 1.32
Blockade of antibody-induced glomerulonephritis with Crry-Ig, a soluble murine complement inhibitor. J Immunol (1998) 1.32